Zevra Therapeutics is a biopharmaceutical company focused on rare diseases and specialty CNS conditions. It develops and commercializes therapies for small patient populations with high unmet medical need, including approved and late-stage assets in rare metabolic and neurological disorders. The business model centers on orphan-drug development, regulatory exclusivity, and specialty pharmacy distribution rather than primary-care mass markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 25.9 | — | 74.7 | — |
| Q3 2025 | 26.1 | — | -0.5 | — |
| Q4 2025 | 34.1 | — | 12.2 | — |
| Q1 2026 | 36.2 | — | 37.9 | — |
| Q2 2026 | 39.7 | 53.3% | 8.8 | -88.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Business Financial Services, Inc. (FBIZ), Anteris Technologies Global Corp. (AVR), Greene County Bancorp, Inc. (GCBC), Cantor Equity Partners IV, Inc. (CEPF), Limbach Holdings, Inc. (LMB), i3 Verticals, Inc. (IIIV)